Table 2.
Neonatal outcomes in buprenorphine-naloxone-exposed infants.
| Study | Birth Parameters | Neonatal Abstinence Syndrome (NAS) Outcomes |
Significant Differences |
|---|---|---|---|
| Debelak [12] |
Mean GA: 38 weeks Mean HC: 33 cm Mean length: 46 cm Mean BW: 2816 g |
NAS requiring pharmacotherapy: 40% Mean duration of NAS treatment: 7 days Mean hospital LOS: 10 days |
No comparison group |
| Dooley [17] |
Mean GA: 39 weeks Mean BW: 3569 g |
NAS requiring pharmacotherapy: 0% | Higher BW in bup-nlx group compared to other opioids group * |
| Gawronski [15] |
Mean GA: 38 weeks Mean HC: 33 cm Mean length: 49 cm Mean BW: 2905 g |
NAS requiring pharmacotherapy: 64% Mean duration of NAS treatment: 32 days Mean hospital LOS: 9 days |
Lower rate of NAS requiring pharmacotherapy in bup-nlx group than in methadone group * |
| Jumah [18] |
Mean GA: 39 weeks Mean BW: 3541 g |
NAS requiring pharmacotherapy: 2% | Higher BW in bup-nlx group compared to illicit opioids group * |
| Mullins [14] |
Mean GA: 39 weeks Mean HC: 36 cm Mean length: 45 cm Mean BW: 2700 g |
NAS requiring pharmacotherapy: 35% Median duration of NAS treatment: 9 days Median hospital LOS: 6 days |
No significant differences |
| Nguyen [13] |
Mean GA: 37 weeks Mean HC: 35 cm Mean length: 45 cm Mean BW: 2700 g |
NAS requiring pharmacotherapy: 19% Mean hospital LOS: 16 days |
No comparison group |
| Wiegand [16] |
Mean GA: 40 weeks Mean HC: 34 cm Mean length: 50 cm Mean BW: 3175 g |
NAS requiring pharmacotherapy: 25% Mean duration of NAS treatment: 11 days Mean hospital LOS: 6 days |
Higher GA at delivery, lower rates of NAS requiring pharmacotherapy and shorter LOS in bup-nlx group compared to methadone group |
Mean GA: mean gestational age at delivery; HC: mean head circumference; BW: birth weight; LOS: length of stay; bup-nlx: buprenorphine-naloxone; * indicates statistically significant difference (p < 0.05).